US High Growth Tech Stocks To Watch

Over the last 7 days, the United States market has risen 1.3% and over the past 12 months, it is up by an impressive 28%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability in line with these positive market trends.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating AppLovin 21.01% 21.71% ★★★★★★ Sandisk 39.13% 40.96% ★★★★★★ Krystal Biotech 29.09% 36.48% ★★★★★★ Reddit 21.88% 25.36% ★★★★★★ Palantir Technologies 30.22% 31.80% ★★★★★★ Fabrinet 21.38% 23.34% ★★★★★★ Marker Therapeutics 64.28% 69.04% ★★★★★★ Tenaya Therapeutics 59.68% 60.87% ★★★★★☆ KVH Industries 28.67% 146.09% ★★★★★☆ Gorilla Technology Group 54.35% 96.69% ★★★★★☆

Click here to see the full list of 69 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Gyre Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $542.75 million.

Operations: Gyre focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily from its Gyre Pharmaceuticals segment, which reported $117.05 million.

Gyre Therapeutics, a player in the high-growth biotech sector, is navigating its path towards profitability with a projected annual earnings growth of 36.78%. Its revenue growth rate stands at an impressive 23.3% annually, significantly outpacing the US market average of 11.8%. The company recently marked a significant milestone with the acceptance of its New Drug Application in China for F351, aimed at treating chronic hepatitis B-induced liver fibrosis—a move that could potentially accelerate its commercialization efforts in a critical market. Despite recent quarterly losses and an executive reshuffle, Gyre's strategic initiatives like this NDA highlight its commitment to addressing substantial unmet medical needs through innovative therapies.

Unlock comprehensive insights into our analysis of Gyre Therapeutics stock in this health report. Examine Gyre Therapeutics' past performance report to understand how it has performed in the past.GYRE Revenue and Expenses Breakdown as at May 2026

Vericel

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America, with a market cap of $1.79 billion.

Story Continues

Operations: Vericel focuses on cellular therapies and specialty biologics, generating revenue primarily from its biotechnology segment, which reported $292.09 million. The company operates within the sports medicine and severe burn care markets across North America.

Vericel Corporation's recent upward revision of its 2026 revenue forecasts to $336 million, coupled with a significant reduction in net losses from the previous year, underscores its robust position in the biotech sector. The company's strategic partnership through a $197 million contract with BARDA for NexoBrid showcases not only a strong client base but also an expansion into critical healthcare infrastructure, potentially boosting long-term stability and market presence. With R&D expenses strategically aligned to foster innovations like MACI for cartilage repair, Vericel is poised to enhance its technological footprint and address pressing medical needs effectively.

Take a closer look at Vericel's potential here in our health report. Evaluate Vericel's historical performance by accessing our past performance report.VCEL Revenue and Expenses Breakdown as at May 2026

AvePoint

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AvePoint, Inc. offers a cloud-native data management software platform across various regions including North America, Europe, the Middle East, Africa, and the Asia Pacific with a market cap of $2.20 billion.

Operations: AvePoint generates revenue primarily from its software and programming segment, amounting to $443.68 million. The company operates in multiple regions, focusing on cloud-native data management solutions.

AvePoint's recent performance and strategic initiatives position it intriguingly in the tech landscape. With a 22% increase in revenue guidance to $515.4 million for 2026, the company is capitalizing on robust demand, highlighted by its first-quarter revenue jump to $117.24 million from $93.06 million year-over-year. The firm's commitment to innovation is evident in its R&D spending, crucial for advancing its AvePoint Confidence Platform and new Rapid Recovery System aimed at enhancing SaaS and cloud data protection. Moreover, AvePoint's proactive share repurchase program, buying back shares worth $202.46 million since early 2026, underscores confidence in its financial health and strategic direction.

Dive into the specifics of AvePoint here with our thorough health report. Gain insights into AvePoint's past trends and performance with our Past report.AVPT Revenue and Expenses Breakdown as at May 2026

Taking Advantage

Click here to access our complete index of 69 US High Growth Tech and AI Stocks. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Interested In Other Possibilities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GYREVCEL and AVPT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments